Literature DB >> 3316581

Effects of cyclosporine in recent-onset juvenile type 1 diabetes: impact of age and duration of disease.

C R Stiller1, J Dupre, M Gent, D Heinrichs, M R Jenner, P A Keown, A Laupacis, R Martell, N W Rodger, B M Wolfe.   

Abstract

Administration of cyclosporine resulted in reduced insulin requirements and improved glycemic control in patients with insulin-dependent diabetes mellitus of recent onset, but the drug was less effective in young children. Renal toxic effects and other problems related to therapy resolved after discontinuation of the drug. Sustained remission seemed dependent on continued administration of cyclosporine. Although short-term control of diabetes may be achieved in some patients, more studies are needed to determine whether cyclosporine can be given safely as maintenance therapy to maintain glycemic control and prevent the long-term consequences of the disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3316581     DOI: 10.1016/s0022-3476(87)80058-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

Review 1.  The case for an autoimmune aetiology of type 1 diabetes.

Authors:  S I Mannering; V Pathiraja; T W H Kay
Journal:  Clin Exp Immunol       Date:  2015-10-21       Impact factor: 4.330

Review 2.  Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.

Authors:  Frank Waldron-Lynch; Kevan C Herold
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

Review 3.  The challenge of modulating β-cell autoimmunity in type 1 diabetes.

Authors:  Mark A Atkinson; Bart O Roep; Amanda Posgai; Daniel C S Wheeler; Mark Peakman
Journal:  Lancet Diabetes Endocrinol       Date:  2018-10-24       Impact factor: 32.069

4.  Diabetes mellitus and exocrine pancreatic insufficiency in a girl with auto-immune haemolysis.

Authors:  P Sifianou; H Tsoka; V Kitra; S Haidas; S Pantelakis
Journal:  Eur J Pediatr       Date:  1992-06       Impact factor: 3.183

Review 5.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

6.  Cyclosporin A treatment of young children with newly-diagnosed type 1 (insulin-dependent) diabetes mellitus. London Diabetes Study Group.

Authors:  M Jenner; G Bradish; C Stiller; P Atkison
Journal:  Diabetologia       Date:  1992-09       Impact factor: 10.122

Review 7.  Clinical pharmacokinetics in infants and children. A reappraisal.

Authors:  G L Kearns; M D Reed
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

8.  Cyclosporine pharmacokinetics and effect in the type I diabetic rat model.

Authors:  L J Brunner; L V Iyer; K Vadiei; W V Weaver; D R Luke
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

9.  Profiling of RNAs from Human Islet-Derived Exosomes in a Model of Type 1 Diabetes.

Authors:  Preethi Krishnan; Farooq Syed; Nicole Jiyun Kang; Raghavendra G Mirmira; Carmella Evans-Molina
Journal:  Int J Mol Sci       Date:  2019-11-25       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.